Cure My Disease

Don't miss your cure!

 Log in / Sign up

What drives survival in advanced prostate cancer? a brazilian study digs into patient data

NCT ID NCT04962919

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study looks at medical records from 584 men in Brazil with castration-resistant metastatic prostate cancer, a form of the disease that no longer responds to hormone therapy. Researchers aim to describe how long these patients survive and to identify their individual characteristics, such as age, other health conditions, and the treatments they received. By comparing outcomes across different national health institutions, the study may reveal patterns that help improve care for this patient group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This study could identify factors linked to better or worse survival, guiding more personalized treatment decisions for prostate cancer patients in Brazil.
What could go wrong
Because this is an observational analysis of medical records, it cannot prove cause and effect. The findings may not apply to other populations or healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

584 people

The number who actually took part.

Started

Jan 2020

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017. Exclusion Criteria: * Diagnosis of localized or locally advanced or metastatic disease sensitive to castration; * Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostatic neoplasms, castration-resistant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostatic neoplasms, castration-resistant

Contacts and locations

Locations

  • A.C.Camargo Cancer Center

    São Paulo, São Paulo, 01525-001, Brazil

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, São Paulo, 01.323-030, Brazil

  • CPO Pucrs

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro Paulista de Oncologia

    São Paulo, São Paulo, Brazil

  • Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO

    Santo André, São Paulo, 09060-650, Brazil

  • Clínica Prognóstica - Centro de Pesquisa Clínica Onconeo

    Campo Grande, Mato Grosso do Sul, 79002-061, Brazil

  • FUNFARME - Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Hospital Napoleão Laureano

    João Pessoa, Paraíba, 58013-140, Brazil

  • Hospital Santa Marcelina

    São Paulo, São Paulo, (11) 2070-6000, Brazil

  • Hospital Sírio-Libanês DF

    Brasília, Federal District, 70200-730, Brazil

  • Hospital de Base do IGESDF - Instituto de Gestão Estratégica em Saúde do Distrito Federal

    Brasília, Federal District, 70335-900, Brazil

  • Hospital de Oncologia do Maranhão Dr. Tarquínio Lopes Filho

    São Luís, Maranhão, 65015-460, Brazil

  • IMIP - Instituto de Medicina Integral Professor Fernando Figueira

    Recife, Pernambuco, 50070-902, Brazil

  • ISEP - Instituto Santa Joana de Ensino e Pesquisa (Rede Américas)

    Recife, Pernambuco, 52011-000, Brazil

  • Irmandade da Santa Casa de Misericórdia de São Paulo - Hospital Central

    São Paulo, São Paulo, 01221-010, Brazil

  • Sírio Libanês

    São Paulo, São Paulo, 01308-050, Brazil

  • UOPECCAN - Hospital do Câncer de Cascavel

    Cascavel, Santa Catarina, 85806-300, Brazil

  • Ética Pesquisa Clínica

    Salvador, Estado de Bahia, 41.950-640, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.